Ann: Corporate Presentation, page-57

As I have stated, in the years preceding the 2022 FDA approval , there are a lot of things NUH could of done better.
I don't want to spend time on this as it doesnt really solve anything, other than to say their strategy lacked coherence and push through. For example no one was really pushing the NHS channel, I understand if there was a guy over there at one point but left. It all seems to me to be a case of trying to get by to make it to the OTC market.
They made it.
Now they need to deliver.
The thing about RealTek and the OEM/s it provides them with more revenue channels plus support in the case of RealTek. They are not totally reliant on one product anymore. At some point I suspect they may well transition out of making buds and purlely focus on being a technology provider in the hearing space.